Evolution and collaboration are the fundamentals of bringing oncology payment reform plans to fruition, say 3 professionals on the front lines.
Mary Caffrey
Advertisement
Mary Caffrey is the Executive Editor for The American Journal of Managed Care® (AJMC®). She joined AJMC® in 2013 and is the primary staff editor for Evidence-Based Oncology, the multistakeholder publication that reaches 22,000+ oncology providers, policy makers and formulary decision makers. She is also part of the team that oversees speaker recruitment and panel preparations for AJMC®'s premier annual oncology meeting, Patient-Centered Oncology Care®. For more than a decade, Mary has covered ASCO, ASH, ACC and other leading scientific meetings for AJMC readers.
Mary has a BA in communications and philosophy from Loyola University New Orleans. You can connect with Mary on LinkedIn.
Articles by Mary Caffrey
Barbara McAneny, MD, founding partner of New Mexico Oncology Hematology Consultants, discusses the challenges in care delivery with step therapy in Medicare Advantage and much-debated home infusion in oncology.
The Community Oncology Alliance Payer Exchange Summit always offers frank discussion, and this year's virtual format promises more of the same.
New results from EMPEROR-Reduced presented at Kidney Week 2020.
The launch comes as major cancer research organizations are calling for ways to increase diversity in clinical trials.
Prompted by students, the medical school overturned a longstanding diagnostic protocol that was not well-founded in evidence.
The recent focus on disparities in health care comes through in the call to action.
Results showed variation by age, gender, and partisan affiliation. But there's agreement on the need to lower the cost of prescription drugs.
More Humana doctors are taking on full global risk under Medicare Advantage than are still using traditional fee-for-service.
Two Americans and a British scientist share the 2020 Prize for Physiology or Medicine for work in the 1970s through the 1990s. The rise of agents to treat hepatitis C virus has created vexing questions in managed care.
The FDA action follows presentation of results in August during the European Society of Cardiology 2020 Virtual Congress.
A new analysis shows that ertugliflozin matched renal results seen in trials for a pair of rival sodium glucose cotransporter 2 (SGLT2) inhibitors.
CMMI's Alexandra Chong, PhD, discusses COVID-19 related flexibilities under the Oncology Care Model, and a panel discusses its successor.
Having biomarker-driven solutions in prostate cancer is important, because they have been lacking.
Researchers suggest that clinical trial design could be shaped by measuring reductions in urinary protein.
A new analysis of ADAURA data shows osimertinib cuts the risk of brain metastases or death by 82% compared with placebo in certain early-stage patients with NSCLC.
Trump administration officials said the new payment incentives represent the biggest change in kidney care in decades.
Kidney cancer rose at least 3% a year during the years studied among adolescents and young adults, according to data from the American Cancer Society.
Members of Congress introduce a bill to force Medicare to cover a drug they say will protect CKD patients during the COVID-19 pandemic.
Drs Joseph Alvarnas and Kashyap Patel, co-chairs of Patient-Centered Oncology Care® 2020, discuss what attendees can look forward to at the September 25 meeting.
An overview of the agenda and speakers who will appear at Patient-Centered Oncology Care 2020, which will be presented September 25 by The American Journal of Managed Care®.
Kidney failure is one of the expensive conditions in health care, but new results from the DAPA-CKD trial could change the equation in favor of prevention.
Data presented during the European Society for Cardiology 2020 Congress were a follow-up to the presentation of VERTIS CV at the American Diabetes Association Scientific Sessions in June.
Below are selected abstracts presented at the European Society of Cardiology 2020 Congress, which was held in a virtual format due to the coronavirus disease 2019 pandemic.
The first study of its kind reports that patients should keep taking well-known heart medications.
A study finds that a partner's participation in a lifestyle change program can be a key to success, especially for weight loss.
Results from the second major renal outcomes trial for an SGLT2 inhibitor affirm the role of the class in preventing renal decline and kidney failure.
The PARALLAX study points to potential benefits from sacubitril/valsartan in heart failure with preserved ejection fraction, which has no approved treatments.
Results from the phase 3 EXPLORER-HCM trial show mavacamten may finally offer a therapeutic solution for patients with hypertrophic cardiomyopathy.
A new study shows that empagliflozin, the diabetes drug that set off a market frenzy 5 years ago, is on par with dapagliflozin for certain heart failure patients.
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Advancing Early Detection and Equitable Access in Alzheimer Disease Care
2
Digital Innovation and New Drugs Converge to Transform CRM Care
3
Blinatumomab Boosts Survival in Pediatric ALL, but Faces Delivery Hurdles
4
Bills to Address Expiring ACA Subsidies Fail to Pass Senate
5
